- Home
- ADIL vs CYAB Comparison
ADIL vs CYAB Comparison
Compare ADIL & CYAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.58
Company Overview
Basic Information| Metric | ADIL | CYAB |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 7.5M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ADIL | CYAB |
|---|---|---|
| Price | $2.58 | $0.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $37.50 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 209.7K |
| Earning Date | 05-13-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.43 |
| 52 Week High | $5.17 | $2.99 |
Technical Indicators
Market Signals| Indicator | ADIL | CYAB |
|---|---|---|
| Relative Strength Index (RSI) | 54.17 | 26.95 |
| Support Level | $1.53 | N/A |
| Resistance Level | $2.56 | $0.73 |
| Average True Range (ATR) | 0.48 | 0.06 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 13.73 | 8.51 |
Price Performance
Historical Comparison ADIL
CYAB
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About CYAB Cyabra Inc. Common Stock
Cyabra Inc is an AI-powered SaaS company that detects and analyzes online disinformation. Its platform uses machine learning to monitor social media and news data in real time, identify fake accounts and harmful narratives, and assess content authenticity and sentiment.